Exelixis, Inc. (NASDAQ:EXEL) Shares Bought by V Square Quantitative Management LLC

V Square Quantitative Management LLC raised its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 37.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,563 shares of the biotechnology company’s stock after acquiring an additional 425 shares during the quarter. V Square Quantitative Management LLC’s holdings in Exelixis were worth $52,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently bought and sold shares of EXEL. Seizert Capital Partners LLC raised its stake in shares of Exelixis by 8.0% during the 3rd quarter. Seizert Capital Partners LLC now owns 469,940 shares of the biotechnology company’s stock worth $12,195,000 after buying an additional 34,875 shares during the last quarter. Los Angeles Capital Management LLC raised its stake in shares of Exelixis by 124.0% during the 3rd quarter. Los Angeles Capital Management LLC now owns 1,790,855 shares of the biotechnology company’s stock worth $46,473,000 after buying an additional 991,494 shares during the last quarter. Tri Ri Asset Management Corp acquired a new position in shares of Exelixis during the 3rd quarter worth $4,396,000. China Universal Asset Management Co. Ltd. raised its stake in shares of Exelixis by 60.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 54,863 shares of the biotechnology company’s stock worth $1,424,000 after buying an additional 20,641 shares during the last quarter. Finally, CWA Asset Management Group LLC acquired a new position in shares of Exelixis during the 3rd quarter worth $577,000. Institutional investors and hedge funds own 85.27% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on EXEL shares. Stephens reaffirmed an “equal weight” rating and set a $29.00 price target on shares of Exelixis in a research note on Wednesday, February 12th. Oppenheimer downgraded shares of Exelixis from an “outperform” rating to a “market perform” rating and cut their target price for the company from $41.00 to $33.00 in a research note on Friday, January 24th. BMO Capital Markets downgraded shares of Exelixis from an “outperform” rating to a “market perform” rating and boosted their target price for the company from $36.00 to $40.00 in a research note on Friday, December 20th. Brookline Capital Management began coverage on shares of Exelixis in a research note on Monday, December 23rd. They issued a “buy” rating for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $40.00 target price on shares of Exelixis in a research note on Thursday, February 13th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $37.24.

Exelixis Stock Performance

Shares of NASDAQ:EXEL opened at $35.00 on Tuesday. Exelixis, Inc. has a 1 year low of $20.14 and a 1 year high of $37.59. The stock has a market capitalization of $10.00 billion, a P/E ratio of 22.44, a PEG ratio of 0.63 and a beta of 0.53. The stock has a 50-day simple moving average of $34.19 and a 200-day simple moving average of $31.01.

Exelixis (NASDAQ:EXEL) last issued its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a return on equity of 20.99% and a net margin of 22.43%. Analysts predict that Exelixis, Inc. will post 1.74 earnings per share for the current year.

Insider Buying and Selling

In related news, EVP Patrick J. Haley sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $35.27, for a total transaction of $352,700.00. Following the transaction, the executive vice president now directly owns 278,665 shares of the company’s stock, valued at approximately $9,828,514.55. The trade was a 3.46 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Jeffrey Hessekiel sold 60,000 shares of the business’s stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $36.67, for a total value of $2,200,200.00. Following the transaction, the executive vice president now directly owns 486,059 shares in the company, valued at $17,823,783.53. This trade represents a 10.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.85% of the stock is currently owned by corporate insiders.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.